U.S. stocks closed rallied on Friday, with the Nasdaq Composite (COMP:IND) securing another back-to-back record, even as ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...

One of the most appealing features of Pfizer's stock is its dividend. The payout recently yielded a hefty 7.4% -- and it's ...

As you can see, life has been very difficult for me. I am 30 years old, yet I look like a seven-year-old girl. I can't walk for a distance; and I can't afford to miss a step and fall down because the ...

The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...

Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

Pfizer bucked the trend of a tepid big pharma Q2 window, raising its full-year profit forecast on the back of strong sales ...

Pfizer (PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 revenue guidance of $61 billion to ...

Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...